Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on August 6, 2025
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
GlobeNewswire
·
August 6, 2025
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – – Positive topline data reported …
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
GlobeNewswire
·
August 6, 2025
Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV; Pivotal, Non-Inferiority Study Expected to be Initiated …
Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
GlobeNewswire
·
August 6, 2025
– Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. ( …
Exagen Inc. to Participate in Third Quarter Investor Conferences
GlobeNewswire
·
August 6, 2025
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th …
Pennant Reports Second Quarter 2025 Results
GlobeNewswire
·
August 6, 2025
EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted …
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
GlobeNewswire
·
August 6, 2025
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited …
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
GlobeNewswire
·
August 6, 2025
Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors …
Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization
GlobeNewswire
·
August 6, 2025
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second …
Voyager Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 6, 2025
- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase …
Keros Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 6, 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor …
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
GlobeNewswire
·
August 6, 2025
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small …
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GlobeNewswire
·
August 6, 2025
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may …
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand growth ZORYVE foam 0.3% received U.S. Food and Drug Administration …
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
GlobeNewswire
·
August 6, 2025
WARREN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment …
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
GlobeNewswire
·
August 6, 2025
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and …
Malted Milk Food Market Set to Reach $9.94 Billion by 2029
EIN Presswire
·
August 6, 2025
The Business Research Company’s Malted Milk Food Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 6, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Malted Milk Food …